nach oben

Arthritis Research & Therapy

Erschienen in:

01.06.2003 | Review

Behçet's disease

verfasst von: Shunsei Hirohata, Hirotoshi Kikuchi

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Behçet's disease is characterized by recurrent aphthous stomatitis, uveitis, genital ulcers, and skin lesions. The role of the HLA-B*51 gene has been confirmed in recent years, although its contribution to the overall genetic susceptibility to Behçet's disease was estimated to be only 19%. The production of a variety of cytokines by T cells activated with multiple antigens has been shown to play a pivotal role in the activation of neutrophils. As regards the treatment, anti-tumor necrosis factor alpha therapy has been shown to be effective for mucocutaneous symptoms as well as for sight-threatening panuveitis, although a randomized, controlled trial is required.

Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M: Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol. 1982, 100: 1455-1458.CrossRefPubMed

Mizuki N, Ohno S, Sato T, Ishihara M, Miyata S, Nakamura S, Naruse T, Mizuki H, Tsuji K, Inoko H: Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behcet's disease. Hum Immunol. 1995, 43: 129-135. 10.1016/0198-8859(94)00159-N.CrossRefPubMed

Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, Nomura E, Onari K, Ohno S, Inoko H: HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease. Tissue Antigens. 2001, 58: 181-184. 10.1034/j.1399-0039.2001.580306.x.CrossRefPubMed

Ota M, Mizuki N, Katsuyama Y, Tamiya G, Shiina T, Oka A, Ando H, Kimura M, Goto K, Ohno S, Inoko H: The critical region for Behcet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet. 1999, 64: 1406-1410. 10.1086/302364.PubMedCentralCrossRefPubMed

Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, Nakamura S, Bahram S, Ohno S, Inoko H: Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum. 1999, 42: 1961-1966. 10.1002/1529-0131(199909)42:9<1961::AID-ANR23>3.0.CO;2-7.CrossRefPubMed

Cohen R, Metzger S, Nahir M, Chajek-Shaul T: Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann Rheum Dis. 2002, 61: 157-160. 10.1136/ard.61.2.157.PubMedCentralCrossRefPubMed

Sano K, Yabuki K, Imagawa Y, Shiina T, Mizuki N, Ohno S, Kulski JK, Inoko H: The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease. Tissue Antigens. 2001, 58: 77-82. 10.1034/j.1399-0039.2001.580202.x.CrossRefPubMed

Kera J, Mizuki N, Ota M, Katsuyama Y, Pivetti-Pezzi P, Ohno S, Inoko H: Significant associations of HLA-B*5101 and B* and lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens. 5108, 54: 565-571. 10.1034/j.1399-0039.1999.540605.x.CrossRef

Gül A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ: Evidence for linkage of the HLA-B locus in Behcet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum. 2001, 44: 239-241. 10.1002/1529-0131(200101)44:1<239::AID-ANR31>3.0.CO;2-X.CrossRefPubMed

10.

Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996, 13: 399-408. 10.1038/ng0896-399.CrossRefPubMed

11.

Malfroy L, Roth MP, Carrington M, Borot N, Volz A, Ziegler A, Coppin H: Heterogeneity in rates of recombination in the 6-Mb region telomeric to the human major histocompatibility complex. Genomics. 1997, 43: 226-231. 10.1006/geno.1997.4800.CrossRefPubMed

12.

Gül A, Hajeer AH, Worthington J, Ollier WE, Silman AJ: Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum. 2001, 44: 2693-2696. 10.1002/1529-0131(200111)44:11<2693::AID-ART449>3.0.CO;2-M.CrossRefPubMed

13.

Touitou I, Magne X, Molinari N, Navarro A, Quellec AL, Picco P, Seri M, Ozen S, Bakkaloglu A, Karaduman A, Garnier JM, Demaille J, Kone-Paut I: MEFV mutations in Behcet's disease. Hum Mutat. 2000, 16: 271-272. 10.1002/1098-1004(200009)16:3<271::AID-HUMU16>3.0.CO;2-A.CrossRefPubMed

14.

Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990, 63: 1099-1112. 10.1016/0092-8674(90)90512-D.CrossRefPubMed

15.

Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T: Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum. 1995, 38: 426-433.CrossRefPubMed

16.

Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W: The histopathology of pathergy: a chronologic study of skin hyperreactivity in Behcet's disease. Int J Dermatol. 1998, 37: 929-933. 10.1046/j.1365-4362.1998.00474.x.CrossRefPubMed

17.

Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P: Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol. 1995, 132: 901-907.CrossRefPubMed

18.

Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989, i: 1093-1096. 10.1016/S0140-6736(89)92381-7.CrossRef

19.

The Behcet's Disease Research Committee of Japan: Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease – a multicenter study. J Rheumatol. 1989, 16: 506-511.

20.

Hirohata S, Oka H, Mizushima Y: Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol. 1992, 140: 410-419. 10.1016/0008-8749(92)90207-6.CrossRefPubMed

21.

Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, Vaughan R, Lehner T: T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol. 1993, 151: 2273-2282.PubMed

22.

Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R, Stanford MR, Sanderson J, Lehner T: Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease. Lancet. 1996, 347: 789-794. 10.1016/S0140-6736(96)90868-5.CrossRefPubMed

23.

Freysdottir J, Lau S, Fortune F: Gammadelta T cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol. 1999, 118: 451-457. 10.1046/j.1365-2249.1999.01069.x.PubMedCentralCrossRefPubMed

24.

Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS: Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol. 2002, 130: 46-54. 10.1016/S0165-5728(02)00208-4.CrossRefPubMed

25.

De Libero G: Sentinel function of broadly reactive human gamma delta T cells. Immunol Today. 1997, 18: 22-26. 10.1016/S0167-5699(97)80010-2.CrossRefPubMed

26.

Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, Kogure M, Inaba G, Sakane T: Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol. 1997, 107: 241-247. 10.1111/j.1365-2249.1997.274-ce1159.x.PubMedCentralCrossRefPubMed

27.

Schondelmaier S, Wesch D, Pechhold K, Kabelitz D: V gamma gene usage in peripheral blood gamma delta T cells. Immunol Lett. 1993, 38: 121-126. 10.1016/0165-2478(93)90176-3.CrossRefPubMed

28.

Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T: Oligoclonal T cell expansions in patients with Behcet's disease. Clin Exp Immunol. 1999, 117: 166-170. 10.1046/j.1365-2249.1999.00931.x.PubMedCentralCrossRefPubMed

29.

Esin S, Gul A, Hodara V, Jeddi-Tehrani M, Dilsen N, Konice M, Andersson R, Wigzell H: Peripheral blood T cell expansions in patients with Behcet's disease. Clin Exp Immunol. 1997, 107: 520-527. 10.1046/j.1365-2249.1997.d01-947.x.CrossRefPubMed

30.

Hirohata S, Hashimoto T: Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol. 1998, 112: 317-324. 10.1046/j.1365-2249.1998.00572.x.PubMedCentralCrossRefPubMed

31.

Frassanito MA, Dammacco R, Cafforio P, Dammacco F: Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999, 42: 1967-1974. 10.1002/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z.CrossRefPubMed

32.

Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K: Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002, 31: 205-210. 10.1080/030097402320318387.CrossRefPubMed

33.

Mantas C, Direskeneli H, Oz D, Yavuz S, Akoglu T: IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol. 2000, 18: 249-251.PubMed

34.

Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, Yamamoto S, Sakane T: Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan. Clin Exp Immunol. 1997, 108: 204-212. 10.1046/j.1365-2249.1997.3611265.x.PubMedCentralCrossRefPubMed

35.

Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U, Jorres A: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol. 2000, 165: 5814-5821.CrossRefPubMed

36.

Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T: Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol. 1999, 162: 4328-4335.PubMed

37.

Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M: Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol. 2001, 19 (suppl 24): S48-S50.PubMed

38.

Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002, 112: 37-43. 10.1016/S0002-9343(01)01048-8.CrossRefPubMed

39.

Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E: Enhancement of endothelial cell E-selection expression by sera from patients with active Behcet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999, 91: 330-337. 10.1006/clim.1999.4687.CrossRefPubMed

40.

Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, Nimura Y: Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology. 2000, 36: 362-371. 10.1046/j.1365-2559.2000.00859.x.CrossRefPubMed

41.

Serdaroglu P: Behçet's disease and the nervous system. J Neurol. 1998, 245: 197-205. 10.1007/s004150050205.CrossRefPubMed

42.

Kidd D, Steuer A, Denman AM, Rudge P: Neurological complications in Behcet's syndrome. Brain. 1999, 122: 2183-2194. 10.1093/brain/122.11.2183.CrossRefPubMed

43.

Kawai M, Hirohata S: Cerebrospinal fluid beta(2)-microglobulin in neuro-Behcet's syndrome. J Neurol Sci. 2000, 179: 132-139. 10.1016/S0022-510X(00)00403-2.CrossRefPubMed

44.

Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H: Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology. 1999, 106: 586-589. 10.1016/S0161-6420(99)90120-3.CrossRefPubMed

45.

Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T: Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol. 1997, 82: 12-17. 10.1006/clin.1996.4268.CrossRefPubMed

46.

Hirohata S, Suda H, Hashimoto T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci. 1998, 159: 181-185. 10.1016/S0022-510X(98)00165-8.CrossRefPubMed

47.

Matsumura N, Mizushima Y: Leucocyte movement and colchicine treatment in Behcet's disease [letter]. Lancet. 1975, 2: 813-CrossRefPubMed

48.

Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H: A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001, 44: 2686-2692. 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H.CrossRefPubMed

49.

Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E: Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002, 138: 467-471. 10.1001/archderm.138.4.467.CrossRefPubMed

50.

Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998, 128: 443-450.CrossRefPubMed

51.

Kari JA, Shah V, Dillon MJ: Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford). 2001, 40: 933-938. 10.1093/rheumatology/40.8.933.CrossRef

52.

Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996, 35: 969-979. 10.1016/S0190-9622(96)90122-X.CrossRefPubMed

53.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997, 337: 1029-1035. 10.1056/NEJM199710093371502.CrossRefPubMed

54.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky PE: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.CrossRefPubMed

55.

Robertson LP, Hickling P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford). 2001, 40: 473-474. 10.1093/rheumatology/40.4.473.CrossRef

56.

Goossens PH, Verburg RJ, Breedveld FC: Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy [concise report]. Ann Rheum Dis. 2001, 60: 637-10.1136/ard.60.6.637.PubMedCentralCrossRefPubMed

57.

Hassard PV, Binder SW, Nelson V, Vasiliauskas EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology. 2001, 120: 995-999.CrossRefPubMed

58.

Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001, 358: 295-296. 10.1016/S0140-6736(01)05497-6.CrossRefPubMed

59.

Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, Akbarian M, Gharibdoust F: High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short term results of 23 patients. Book of Abstracts. 10th International Conference on Behçet's Disease; Berlin. 69-June 27–29, 2002

Titel: Behçet's disease
verfasst von: Shunsei Hirohata
Hirotoshi Kikuchi
Publikationsdatum: 01.06.2003
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 3/2003
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar757

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Smoking–gender interaction and risk for rheumatoid arthritis

New insights into integrin signalling: implications for rheumatoid arthritis synovial fibroblasts

Introduction

Osteoclast-independent bone resorption by fibroblast-like cells

B cells as a therapeutic target in autoimmune disease